{"id": "1334539546743218181", "creation": 1607013997.0, "user_id": "19507168", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 0, "reply_count": 1, "like_count": 0, "quote_count": 0}}, "quoted": "1334518849312583680", "text": "Hardly a new #Regulatory topic but timely for prospective #COVID19 #vaccine pre/post-market considerations, #RealWorldEvidence. While it's no #RCT gold-standard of data quality, #RWE is an approach that ought not be overlooked to complement post-market monitoring reqmts. #MedTech https://t.co/91BLjxelKT", "first_save": 1634559108.199414, "hashtags": ["#REGULATORY", "#COVID19", "#VACCINE", "#REALWORLDEVIDENCE", "#RCT", "#RWE", "#MEDTECH"]}